This journal is devoted to all areas of transfusion medicine. These include the quality and security of blood products, therapy with blood components and plasma derivatives, transfusion-related questions in transplantation, stem cell manipulation, therapeutic and diagnostic problems of homeostasis, immuno-hematological investigations, and legal aspects of the production of blood products as well as hemotherapy. Both comprehensive reviews and primary publications that detail the newest work in transfusion medicine and hemotherapy promote the international exchange of knowledge within these disciplines. Consistent with this goal, continuing clinical education is also specifically addressed.

Transfusion Medicine and Hemotherapy

Editor-in-Chief
P. Schlenke, Graz

Associate Editors
P. Bugert, Mannheim
A. Buser, Basel
J. Dreier, Bad Oeynhausen
Britta Eiz-Vesper, Hannover
B.M. Frey, Zurich

C. Gassner, Zurich
H.-G. Heuft, Hannover
A. Humpe, Munich
W. Korte, St. Gallen
B. Mansouri-Taleghani, Bern
A. Pruß, Berlin
A. Sputtek, Bremen
F.F. Wagner, Springe

Official Journal of the
Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie

Transfusion Medicine and Hemotherapy

Founded: 1973
Category: Clinical and Basic Research
Fields of Interest: Hematology, Immunology

Listed in bibliographic services, including:
PubMed/PubMed Central, Web of Science, Google Scholar, Scopus, Embase

2019: Volume 46
6 issues per volume
Language: English
ISSN 1660–3796
e-ISSN 1660–3818

Impact Factor: 2.152

More information at www.karger.com/tmh

Selected contributions
• HOXB4 Increases Runx1 Expression to Promote the de novo Formation of Multipotent Hematopoietic Cells: Teichweyde, N.; Horn, P.A.; Klump, H. (Essen)
• Ex vivo Generation of Genetically Modified Macrophages from Human Induced Pluripotent Stem Cells: Ackermann, M.; Kuhn, A.; Kunkiel, J.; Merkert, S.; Martin, U.; Moritz, T.; Lachmann, N. (Hannover)
• Biophysical and Biochemical Markers of Red Blood Cell Fragility: Orbach, A.; Zelig, O.; Yedgar, S.; Barshtein, G. (Jerusalem)
• Thrombosis in Inherited Fibrinogen Disorders: Korte, W. (St. Gallen); Poon M.-C. (Calgary, AB); Iorio, A. (Hamilton, ON); Makris, M. (Sheffield)
• Administration Safety of Blood Products – Lessons Learned from a National Registry for Transfusion and Hemotherapy Practice: Frietsch, T. (Mannheim); Thomas, D. (Swansea); Schöler, M. (Mannheim); Fleiter, B. (Rätigen); Schipplick, M. (Leonberg); Spannagl, M. (Munich); Knels, R. (Dresden); Nguyen, X.D. (Mannheim)
• Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy: Kellner, C.; Otte, A. (Kiel); Cappuzzello, E. (Padua); Klausz, K.; Peipp, M. (Kiel)
• Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy: Koch, J.; Tesar, M. (Heidelberg)
• Global Registration Identifier for Donors (GRID) of Hematopoietic Stem Cells: Road to Automation and Safety: Neller, J.K. (Ulm); Ashford, P. (San Bernardino, CA); van Veen, C. (Leiden); Humpe, A. (Magdeburg)